Evaluación de la presencia de inmunidad humoral específica contra SARS-COV2 causante del COVID-19 en mujeres de la UPS sede Quito en edades comprendidas entre 24 a 30 años, posterior al proceso de vacunación.

Abstract

The emergence of vaccines against SARS CoV-2 contributed to the control and containment of the pandemic, reducing the risks of hospitalization and death. This event prompted research on the development and duration of immunity after infection or vaccination and how it slows the spread of the virus around the world. However, in Ecuador, there are no seroprevalence studies after vaccination and the determination of post-vaccination immunity as a possible indicator of sufficient immunity has not been considered within the epidemiological control strategies. That is why the present study was designed with the main objective of evaluating the presence of specific humoral immunity against SARS-CoV2 causing COVID-19 in women from the UPS Quito headquarters aged between 24 to 30 years, after the process of vaccination. This study was carried out in stages, in the first stage authorization was obtained through the competent authorities to start the investigation, then capillary blood sampling was carried out using the IgG/IgM rapid test kit from Biomerica's COVID-19 and the collection of epidemiological data from the selected population, and in the second stage, a database was generated, from which 147 capillary blood sample results were evaluated and analyzed using tables of contingency in the statistical program Infostat. The results showed that the type of vaccine did not influence the generation of antibodies against SARS-CoV2 in women between 24 and 30 years of age after the vaccination process, while the number of doses administered did influence. Therefore, it is concluded that the boosters of the vaccines provide immunity in women between 24 and 30 years after the vaccination process.